CompletedNot Applicable

Use of New Antibiotics in Sweden

Sweden41 participantsStarted 2021-11-01

Plain-language summary

Antibiotic resistance is a growing global health problem of great concern, especially multidrug-resistant Gram-negative bacteria. In recent years some new antibiotics targeting these bacteria have been developed. The aim of this study is to investigate how these new antibiotics are used in Sweden. Information will be collected on patients, types of infections, dosing strategies, treatment outcome and occurrence of antibiotic resistance during treatment. The overall goal is to increase the knowledge about how these antibiotics are prescribed and how to optimize the use of them in clinical practice.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Treatment with any of the following antibiotics; cefiderocol, ceftazidim-avibactam, ceftolozan-tazobactam, fosfomycin, meropenem-vaborbactam or imipepenem-relebactam against an acute infection. Exclusion Criteria: * Ongoing treatment with any of the above mentioned antibiotics for more than seven days at the point of inclusion.

What they're measuring

Clinical cure

Timeframe: 30 days from enrollment

Microbiological cure

Timeframe: 30 days from enrollment

All-cause mortality

Timeframe: 30 days from enrollment

Trial details

NCT IDNCT05048693

SponsorUppsala University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-12-30

View on ClinicalTrials.gov More Multi-antibiotic Resistance trials